top of page

GPCR Retreat Program

Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Date & Time

Friday, November 3rd / 9:20 AM

Abstract


Coming Soon

About Ali Salahpour


"Dr. Salahpour did his undergrad (1993-1996) and PhD (1996-2002) at University of Montreal in the Department of Biochemistry. His PhD work was under the supervision of Dr. Michel Bouvier working on the topic of GPCR dimerization/oligomerization. In November of 2002, he joined the lab of Dr. Marc Caron at Duke University for his post-doctoral training. In the Caron lab, Dr. Salahpour worked on Dopamine Transporter and its role on regulating dopamine transmission and homeostasis. In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has continued working on dopamine transmission and homeostasis and the role of several of key modulators of the dopamine system, including the dopamine transporter (DAT), the Vesicular Monoamine Transporter 2 (VMAT2), Tyrosine Hydroxylase (TH) and Trace Amine Associate Receptor 1 (TAAR1)."



Ali Salahpour on the web


Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec